Valued at a market cap of $27.5 billion, Kenvue Inc. (KVUE) is a number one shopper well being firm that manages among the world’s most trusted manufacturers, together with Tylenol, Neutrogena, Listerine, Aveeno, Band-Assist, and Johnson’s Child. The Summit, New Jersey-based firm, focuses on science-backed, insight-driven “on a regular basis care” options.
This family & private merchandise firm has considerably underperformed the broader market over the previous 52 weeks. Shares of Kenvue have declined 37.8% over this time-frame, whereas the broader S&P 500 Index ($SPX) has gained 17.4%. Furthermore, on a YTD foundation, the inventory is down 33.3%, in comparison with SPX’s 16% rise.
Narrowing the main target, Kenvue has additionally lagged behind the Client Staples Choose Sector SPDR Fund’s (XLP) 4.7% drop over the previous 52 weeks and a pair of.7% fall on a YTD foundation.
Shares of Kenvue gained 1.5% after its combined Q2 earnings launch on Aug. 7. As a result of a 4.2% decline in natural gross sales, pushed by weaker volumes throughout all three of its reportable segments, the corporate’s web gross sales dropped 4% year-over-year to $3.8 billion, lacking consensus estimates by a slight margin. Nonetheless, on the brighter aspect, whereas its adjusted EPS of $0.29 additionally decreased 9.4% from the identical interval final 12 months, it topped analyst expectations by a penny.
For the present fiscal 12 months, ending in December, analysts anticipate Kenvue’s EPS to say no 13.2% 12 months over 12 months to $0.99. The corporate’s earnings shock historical past is promising. It exceeded or met the consensus estimates in every of the final 4 quarters.
Among the many 16 analysts protecting the inventory, the consensus score is a “Average Purchase,” which relies on 5 “Sturdy Purchase,” 10 “Maintain,” and one “Sturdy Promote” score.
This configuration is barely much less bullish than a month in the past, with six analysts suggesting a “Sturdy Purchase” score.
On Oct. 29, Canaccord Genuity lowered its score on Kenvue to “Maintain” and minimize its worth goal to $15, indicating a 5.3% potential upside from the present ranges.
The imply worth goal of $19.29 represents a 35.5% premium from Kenvue’s present worth ranges, whereas the Avenue-high worth goal of $23 suggests an upside potential of 61.5%.
On the date of publication, Neharika Jain didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All data and knowledge on this article is solely for informational functions. This text was initially revealed on Barchart.com